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Dithiocarbamates (DTCs) have recently been reported as powerful inhibitors of NF-kB activation in a
number of cell types. Given the role of this transcription factor in the regulation of gene expression in the
inflammatory response, NF-kB inhibitors have been suggested as potential therapeutic drugs for inflammatory
diseases. We show here that DTCs inhibited both interleukin 2 (IL-2) synthesis and membrane expression of
antigens which are induced during T-cell activation. This inhibition, which occurred with a parallel activation
of c-Jun transactivating functions and expression, was reflected by transfection experiments at the IL-2
promoter level, and involved not only the inhibition of NF-kB-driven reporter activation but also that of
nuclear factor of activated T cells (NFAT). Accordingly, electrophoretic mobility shift assays (EMSAs) indi-
cated that pyrrolidine DTC (PDTC) prevented NF-kB, and NFAT DNA-binding activity in T cells stimulated
with either phorbol myristate acetate plus ionophore or antibodies against the CD3–T-cell receptor complex
and simultaneously activated the binding of AP-1. Furthermore, PDTC differentially targeted both NFATp and
NFATc family members, inhibiting the transactivation functions of NFATp and mRNA induction of NFATc.
Strikingly, Western blotting and immunocytochemical experiments indicated that PDTC promoted a transient
and rapid shuttling of NFATp and NFATc, leading to their accelerated export from the nucleus of activated T
cells. We propose that the activation of an NFAT kinase by PDTC could be responsible for the rapid shuttling
of the NFAT, therefore transiently converting the sustained transactivation of this transcription factor that
occurs during lymphocyte activation, and show that c-Jun NH2-terminal kinase (JNK) can act by directly
phosphorylating NFATp. In addition, the combined inhibitory effects on NFAT and NF-kB support a potential
use of DTCs as immunosuppressants.
The interaction of T lymphocytes with antigens triggers a
complex signaling cascade that switches on the gene program
leading to T-cell activation. During this process, T cells express
the autocrine growth factor interleukin 2 (IL-2), which pro-
motes cell proliferation by interacting with its receptor, also
expressed by activated T cells. The transcriptional regulation
of the IL-2 gene has been extensively analyzed with the IL-2
promoter, a 275-bp region located upstream of the transcrip-
tional start site of the gene. Cis-Acting elements for several
transcription factors have been identified within this regulatory
region. The factors which bind to these motifs include AP-1,
NF-kB, Oct-1, and nuclear factor of activated T cells (NFAT)
family proteins (reviewed in references 15 and 26).
The transcription factor NFAT plays an essential role in
IL-2 gene expression (59). Binding sites for NFAT have also
been found within the promoter regions of several cytokines,
including granulocyte-macrophage colony-stimulating factor,
tumor necrosis factor alpha, IL-3, IL-4, and IL-5 (10–12, 17, 27,
34, 44, 64). NFAT is composed of a complex whose binding
specificity is mediated by a cytosolic subunit and an inducible
nuclear component comprised of AP-1 family members. The
cytoplasmic subunit is encoded by a family of genes constituted
by at least four structurally related NFAT members, NFATp/
NFAT1, NFATc, NFAT3, and NFATX/NFAT4/NFATc3 (20,
23, 31, 35, 37, 43). These members translocate to the nucleus
upon calcium mobilization during T-cell activation involving
the calcineurin-dependent dephosphorylation of the transcrip-
tion factor. Blockade of this pathway by the immunosuppres-
sive drugs cyclosporin A (CsA) and FK 506 results in inhibition
of the phosphatase activity of calcineurin, thus preventing the
subsequent dephosphorylation and translocation of NFAT to
the nucleus. Hence, NFAT can be considered a secondary
target of the action of the immunosuppressive drugs, whose
inhibition accounts, at least in part, for the transcriptional
inhibitory effects of the immunosuppressants (28, 55). In the
nucleus, NFAT family proteins can interact with the inducible
nuclear component formed by Fos and Jun family members to
bind cooperatively and transactivate NFAT sites in vitro (8, 15,
25, 26, 48).
Dithiocarbamates (DTCs) are antioxidant compounds that
have been shown to exert opposite effects on the activity of
NF-kB and AP-1 transcription factors. In T cells, DTCs inhibit
activation of NF-kB by a number of stimuli that promote the
production of reactive oxygen intermediates proposed as com-
mon second messengers in the activation of the transcription
factor (3, 52, 57). In contrast, AP-1 has been shown to be
activated by DTCs in a number of cell types, including T
lymphocytes (18, 57, 58). Although the precise primary cellular
targets involved in DTC-mediated changes in the activity of
these transcription factors have not been identified so far, the
inhibition by pyrrolidine DTC (PDTC) of NF-kB involves the
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blockade of IkB-a phosphorylation (66), whereas PDTC-me-
diated AP-1 activation in T lymphocytes is accompanied by a
strong and sustained activation of c-Jun NH2-terminal kinase
(JNK) (18).
Since DTCs affect the activity of transcription factors impor-
tant for gene regulation during the T-cell activation process,
we analyzed here the effects of these agents on IL-2 gene
expression and on the activity of its promoter region, which is
in turn regulated by multiple transcription factors that inte-
grate signals transmitted from different pathways. We found
that despite the activation exerted on AP-1, DTCs inhibited
NFAT-dependent transactivation and binding by mechanisms
different from those mediated by the immunosuppressive
drugs FK 506 and CsA. We discuss the potential benefits de-
rived from the use of DTCs as immunosuppressants and spec-
ulate on the putative involvement of an NFAT kinase mediat-
ing the inhibitory effects of these agents on the NFATp
transactivation functions.
MATERIALS AND METHODS
Cell culture and reagents. Jurkat and PEER cells (ab and gd T-cell lines) were
maintained in RPMI 1640 medium (Gibco-BRL) supplemented with 10% fetal
bovine serum. Peripheral blood mononuclear cells were isolated from healthy
volunteers, and venous blood was drawn with heparin syringes and diluted in an
equal volume of saline solution. The suspension was layered over a Ficoll-
Hypaque cushion and centrifuged. Mononuclear cells were collected, washed,
and resuspended in RPMI 1640 medium supplemented with 10% fetal bovine
serum. The cells were then incubated at 37°C for 1 h on plastic dishes to remove
monocytes. The peripheral blood lymphocytes (PBLs) (5 3 105 per well) were
then stimulated with immobilized anti-CD3 monoclonal antibody (MAb) in a
24-well tissue culture plate previously precoated for 2 h with 100 ml of a 10-mg/ml
solution of UCHT.1 anti-CD3 antibody (9) at 37°C. Phorbol 12-myristate 13-
acetate (PMA), PDTC, diethyl DTC (DDTC), disulfiram, butylated hydroxyan-
isole (BHA), N-acetylcysteine (NAC), and the calcium ionophore A23187 were
purchased from Sigma. CsA was obtained from Sandoz.
Antibodies, flow cytometry analysis, and IL-2 immunoassay. After different
treatments, cells were collected by centrifugation, resuspended in phosphate-
buffered saline (PBS), and incubated at 4°C for 30 min with hybridoma culture
supernatant of TP1/55 anti-CD69 MAb (50) or fluorescein isothiocyanate-con-
jugated anti-CD25 antibody from Becton Dickinson. Cells were washed with PBS
and resuspended in 300 ml of propidium iodide (2 ng/ml), and bound anti-CD69
antibody was detected with fluorescein isothiocyanate-conjugated rabbit F(ab9)2
anti-mouse immunoglobulin G (IgG) (Dako A/S, Roskilde, Denmark). The
supernatant from the myeloma P3X63 was used as a negative control. The
anti-CD3 MAbs were purified by affinity chromatography on a protein A-Sepha-
rose column. When cells were activated with anti-CD3 antibodies, the biotinyl-
ated TP1/55 MAb was used to monitor CD69 expression. In this case, biotinyl-
ated TEA 2/1 (anti-ELAM-1 MAb) was used as a negative control. Samples were
analyzed by flow cytometry in a FACScan cytofluorometer (Becton Dickinson,
Mountain View, Calif.). Analysis was performed with viable cells (typically
higher than 95%) as determined by staining with the fluorochrome propidium
iodide. Since we observed variability among different batches of Jurkat cells
regarding the doses of DTCs required to achieve maximal inhibition of mem-
brane markers of T-cell activation, we routinely performed flow cytometry anal-
ysis of CD69 with doses of PDTC ranging between 50 and 200 mM to select the
minimal dose of PDTC that achieved the maximal inhibition in activated Jurkat
cells.
IL-2 levels were measured with an enzyme-linked immunosorbent assay kit
purchased from Amersham. Cell supernatants from Jurkat T cells were collected
20 h after stimulation.
Plasmid constructs. The reporter constructs NFAT-Luc, containing three
tandem copies of the NFAT binding site fused to the IL-2 minimal promoter, and
IL-2-Luc, containing the region spanning from 2326 to 145 of the human IL-2
promoter or enhancer have been described previously (16) and were provided by
G. Crabtree. The pKBF-Luc construct includes a trimer of the NF-kB motif of
the H-2Kb gene upstream of the herpes simplex virus thymidine kinase minimal
promoter driving the luciferase reporter gene (73).
The GAL4 plasmids RSV-GAL4-DBD (RSV is Rous sarcoma virus) and
GAL4-hNFAT1(1–415) have been described previously (32). The GAL4-
hNFAT1(1–415) plasmid encodes the transactivation domain of NFAT1/p (ami-
no acids 1 to 415) in frame with the GAL4 DNA binding domain (DBD).
RSV-GAL4-DBD is the parental vector including just the DBD (amino acids 1
to 147) of GAL4. RSV–GAL4–c-Jun (wild type) and RSV–GAL4–c-Jun S1 1 S2,
constructs that encode the wild-type transactivation domain of c-Jun and this
domain mutated in its phosphorylation sites (Ser 63 and Ser 73), respectively
(45), were gifts from P. Angel. The GAL4-Luc reporter plasmid, including five
GAL4 DNA binding sites fused to the luciferase gene (provided by R. Perona)
has been described previously (39).
Transient transfections and luciferase assays. Jurkat cells (2 3 107) were
transiently transfected with 5 mg of luciferase reporter plasmid with 10 mg of
Lipofectin reagent (Gibco BRL) for 8 h in 1 ml of OPTIMEM (Gibco BRL) or
were cotransfected with 2 mg of GAL4 expression plasmids and 4 mg of GAL4-
Luc construct, with 10 mg of Lipofectin reagent added for 8 h in 1 ml of
OPTIMEM in transactivation experiments. The cells were then diluted in com-
plete medium and after 36 h were preincubated or not with different concentra-
tions of PDTC for 2 h and stimulated with PMA plus A23187 for 3 or 8 h as
indicated. Cells were then collected by centrifugation and lysed according to the
instructions of a Promega luciferase assay kit. The luciferase activity was mea-
sured for 30 s with a Lumat LB9501 luminometer (Berthold, Germany).
Nuclear extracts and EMSAs. For nuclear extracts, Jurkat cells were pre-
treated or not with 100 mM PDTC for 2 h and further stimulated for 1, 4, or 8
additional h with 20 ng of PMA per ml plus 1 mM A23187. PBLs were also
pretreated or not with PDTC for 2 h and then washed with PBS and incubated
with hybridoma culture supernatant of anti-CD3 SPV-T3 MAb (62) for 30 min
at 4°C. Next, cells were incubated with Dynabeads M-450 coupled to sheep
anti-mouse IgG (Dynal A.S., Oslo, Norway) for 30 min under bidirectional
rotation at 4°C. The Dynabeads with T cells attached were collected with a
suitable magnet, resuspended in ice-cold RPMI 1640 with 10% fetal bovine
serum at 4°C, and incubated at 37°C for 15, 60, and 120 min in the presence or
absence of PDTC. Small-scale nuclear extracts were then prepared according to
a procedure described elsewhere (54) with some modifications. Briefly, cells were
collected by centrifugation, washed once with PBS, and resuspended in 400 ml of
ice-cold buffer A (10 mM HEPES [pH 7.6], 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 0.75 mM spermidine, 0.15 mM spermine, 1 mM dithiothreitol [DTT], 0.5
mM phenylmethylsulfonyl fluoride [PMSF], 10 mM Na2MoO4, 1 mg of pepstatin
per ml, 2 mg each of leupeptin and aprotinin per ml). After 15 min on ice, 0.6%
(vol/vol) Nonidet P-40 was added, and cells were vortexed and centrifuged in a
microcentrifuge for 30 s at 15,000 3 g. The nuclear pellet was extracted with 50
ml of buffer C (20 mM HEPES [pH 7.6], 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, 10 mM Na2MoO4, 1 mg of pepstatin per ml,
4 mg of leupeptin per ml, 4 mg of aprotinin per ml) for 30 min on a rocking
platform and further centrifuged at 15,000 3 g for 10 min. The supernatants were
collected and stored at 280°C. All steps were performed on ice or at 4°C. Protein
concentrations were determined by Bradford assay.
Gel retardation assays were performed as previously described (18) with some
modifications. Nuclear extracts (1 to 5 mg) were incubated with 1 mg of poly(dI-
dC) and 3 ml of 53 DNA binding buffer (10% [wt/vol] polivinylethanol, 12.5%
[vol/vol] glycerol, 50 mM Tris [pH 8], 2.5 mM EDTA, 2.5 mM DTT) in a final
volume of 13 ml on ice for 10 min. Next, 25,000 cpm (2.5 3 107 to 5 3 107
cpm/mg) of 32P-labeled double-stranded oligonucleotides (2 ml) was added, and
this mixture was incubated at room temperature for 40 min. In competition
experiments, 30-fold molar excess of unlabeled homologous oligonucleotides was
added to the binding reaction mixture prior to the addition of the probe. The
DNA-protein complexes were resolved by electrophoresis on a 4% nondenatur-
ing polyacrylamide gel. The sequences of the oligonucleotides (59 to 39) used as
probes in EMSAs were gatcGGAGGAAAAACTGTTTCATACAGAAGGCGT
(distal NFAT site of human IL-2 promoter), gatcGGGATTTCACCT (NF-kB
binding site of human IL-2 promoter), and GCCCCCTCTGACTCATGCTG
ACA (nucleotides 268 to 246, including the AP-1 site of the CD11c promoter).
The pairs of complementary synthetic oligonucleotides were annealed and
labeled with the Klenow fragment of the DNA polymerase I (for NF-kB and
NFAT oligonucleotides) or with the avian myeloblastosis virus reverse transcrip-
tase in the case of AP-1 oligonucleotide.
Supershift assays were performed by incubating the antiserum (0.5 ml) and
nuclear extract for 15 min at 4°C, before addition of the probe to the binding
reaction mixture. The antiserum 67.1, specific for NFAT1/p, has been previously
described (21).
Western blot analysis. After the different treatments, cells (2 3 106) were
washed with ice-cold PBS and resuspended in hypotonic buffer (10 mM Tris-Cl
[pH 7.5], containing 10 mM NaCl, 3 mM MgCl2, 1 mM PMSF, 0.5 mM DTT, 0.1
mM EGTA, 2 mM leupeptin, 1 mg of aprotinin per ml, and 0.05% Nonidet P-40).
Cells were then centrifuged at 650 3 g to pellet the nuclei, and the supernatant
was removed. The nuclear pellet was washed in the hypotonic buffer without
detergent and resuspended in Laemmli buffer. For the preparation of whole-cell
extracts, total proteins from the different cells (106) were extracted as previously
described (2). Nuclear and total extracts were boiled and separated by sodium
dodecyl sulfate (SDS)-polyacrylamide (6%) gel electrophoresis under reducing
conditions. Gels were transferred to nitrocellulose membranes that were incu-
bated in blocking solution (5% [wt/vol] skim milk in Tris-buffered saline [TBS]
buffer) for 90 min at room temperature, washed twice in TBS-T (TBS, 0.05%
Tween 20), and incubated with antiserum 67.1 (0.03% [vol/vol]) in TBS-T for 2 h.
Membranes were then washed four times for 5 min each in TBS-T, and perox-
idase-labeled goat anti-rabbit IgG (Pierce) was incubated for 90 min at room
temperature. After three washes with TBS-T and one wash with H2O, mem-
brane-bound antibody was visualized with the Amersham ECL (enhanced chemi-
luminescence) detection reagent.
Solid-phase JNK assays. After the indicated treatment, PBLs (5 3 106 per
sample) were lysed for 15 min on ice with lysing buffer (20 mM HEPES [pH 7.6],
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10 mM EGTA, 40 mM b-glycerophosphate, 1% Nonidet P-40, 2.5 mM MgCl2, 2
mM sodium orthovanadate, 1 mM DTT, 1 mM PMSF, 20 mg of aprotinin per ml,
20 mg of leupeptin per ml) and centrifuged at 12,000 3 g for 10 min at 4°C. The
supernatants were collected and incubated with 0.3 mg of a rabbit polyclonal
anti-JNK-1 antibody (Santa Cruz Biotech, Inc.). One hour after this incubation,
protein A beads were added, and the mixture was incubated at 4°C for an
additional 2 h. The immune complexes were washed three times with PBS that
contained 1% Nonidet P-40 and 2 mM vanadate and once with kinase buffer (20
mM HEPES [pH 7.6], 2 mM DTT, 10 mM b-glycerophosphate, 20 mM MgCl2,
0.1 mM Na3VO4). After the washing, the supernatant was removed and the
kinase reaction was initiated by addition of 40 ml of kinase buffer containing 20
mM cold ATP, 0.1 mCi of [g-32P]ATP, and 1 mg of GST–c-Jun(1–79) (GST is
glutathione S-transferase) or GST–NFATp(1–415) per reaction at 30°C for 20
min. The reaction was stopped by addition of 10 ml of 53 Laemmli buffer, and
this mixture was boiled for 5 min and then analyzed by SDS gel electrophoresis
on a 12% acrylamide gel. GST–c-Jun(1–79) and GST-NFATp(1–415) proteins
were isolated from 250 ml of bacterial cultures expressing pGEX–c-Jun(1–79)
plasmid (19) or pGEX2T-NFATp(1–415) (33) plasmid, respectively, with GSH-
Sepharose 4B beads (Pharmacia Biotech., Inc.).
Northern blot analysis. After different treatments, Jurkat cells were harvested,
and total RNA was isolated with the Ultraspec system (Biotecx Laboratories,
Inc.). Poly(A)1 RNAs were purified by using the PolyATtract mRNA isolation
system III (Promega). For Northern blot analysis, poly(A)1 RNA from each
sample (0.5 mg) was denatured, electrophoresed on a 1% formaldehyde agarose
gel, and blotted onto a nitrocellulose membrane. After UV cross-linking, the
filters were hybridized overnight at 42°C with the corresponding specific probes:
a 2.2-kb EcoRI fragment of the NFATc cDNA (40), a 0.8-kb PstI fragment of
IL-2 cDNA, a 0.8-kb HindIII-PstI fragment of c-Jun cDNA, and a 0.6-kb
HindIII-BamHI fragment of the b-actin cDNA.
Immunocytochemical localization of NFATp and NFATc. Jurkat cells (107)
were electroporated with 10 mg of pEF-BOS NFAT1 plasmid, which expresses
influenza virus hemagglutinin (HA)-tagged NFATp (33), or 20 mg of
pSH102CD418 (provided by G. Crabtree), which expresses HA-tagged NFATc (1
to 418) (43). Forty-eight hours after transfection, cells were plated on polylysine-
coated coverslips and either were left untreated or were incubated with PDTC
(50 mM) for 2 h before stimulation with PMA plus Ca21 ionophore as indicated.
The subcellular localization of NFATp was analyzed by immunofluorescence
with anti-HA antibody (12CA5) as previously described (33). The percentages of
cells displaying nuclear or cytoplasmic staining were scored visually after count-
ing of at least 150 HA-expressing cells in the experiments shown. Two or four
different fields are presented at each time point analyzed.
RESULTS
Inhibition of T-cell activation by DTCs. Signals transduced
by the activation of T-cell receptor (TCR) induce the synthesis
of IL-2 and the expression of IL-2 receptors (IL-2Rs) and
other activation antigens (14, 70). The activation process can
be mimicked by simultaneous treatment of T cells with stimuli
that activate protein kinase C and elevate intracellular Ca21,
such as phorbol esters and calcium ionophores (15, 67). To
determine the effects of the different antioxidants on the T-cell
activation process, flow cytometry analysis of Jurkat cells acti-
vated with the phorbol ester PMA and the calcium ionophore
A23187, either preincubated or not with different DTCs,
PDTC, or DDTC and its disulfide-linked form disulfiram, were
carried out. As shown in Fig. 1, doses of DTCs in the range of
50 to 100 mM inhibited the upregulated expression of the
T-cell activation antigen CD69 and the IL-2Ra chain (CD25)
induced by PMA plus ionophore. The pretreatment with DTCs
strongly inhibited the cell surface expression of CD25, whereas
that of CD69 was not totally blocked. Conversely, DTCs in-
duced low levels of expression of CD69 that persisted but were
not further increased by subsequent stimulation with PMA
plus ionophore. Similar results were obtained by using unfrac-
tionated PBLs stimulated with PMA plus ionophore, and in-
hibition of CD69 membrane expression was also observed in
the T-cell population activated through the CD3-TCR complex
(Fig. 1B).
The synthesis of IL-2 requires the efficient integration of
signals transmitted through different pathways during T-cell
activation. We next explored whether the inhibitory effects
observed with the DTCs were also reflected at the IL-2 expres-
sion level. The IL-2 secretion by Jurkat cells in response to
PMA plus ionophore was inhibited, in a dose-dependent man-
ner, by the different antioxidants tested (Fig. 2). DTCs also
blocked IL-2 secretion at concentrations ranging from 20 to 50
mM. Since DDTC and disulfiram, but not PDTC, have been
reported to produce acidification in long-term-treated cell cul-
tures (53) and PDTC displayed a very potent inhibitory effect
on membrane expression of T-cell activation markers and IL-2
secretion, we used this derivative of DTC to further character-
ize the mechanism accounting for the interference with the
T-cell activation process observed.
Blockade of IL-2 transcription by DTCs. To characterize the
molecular mechanisms involved in the inhibition of the IL-2
secretion by DTCs, we performed Northern blot analysis of
Jurkat cells treated or not with PDTC and then stimulated with
PMA plus ionophore. IL-2 mRNA steady-state levels, detected
as early as 4 h and strongly increased after 8 h of stimulation,
were totally abrogated in cells exposed to PDTC (Fig. 3A). The
FIG. 1. Effect of DTCs on membrane expression of T-cell activation markers.
(A) Flow cytometry profiles of CD69 and CD25 expression in Jurkat cells either
untreated or treated with different DTCs (thin lines) are compared with those of
cells stimulated with PMA plus Ca21 ionophore (thick lines) or cells pretreated
with the DTCs for 2 h and further stimulated with PMA plus ionophore (dotted
lines). In the control panel (2) dotted lines indicated the staining with P3X63
myeloma supernatant, used as a negative control, and thin lines indicate the
baseline expression of CD69 or CD25. DTCs were added for 16 h at doses of 100
mM (PDTC and DDTC) and 50 mM (disulfiram). PMA (20 ng/ml) and Ca21
ionophore A23187 (1 mM) were also added for 16 h. (B) Profiles of CD69
expression in PBLs untreated or pretreated for 2 h with 50 mM PDTC and
further stimulated with 20 ng of PMA per ml plus 1 mM ionophore or by
incubation in UCHT.1 (anti-CD3)-coated cells (thin lines) are compared with
those of cells stimulated with PMA plus ionophore or immobilized anti-CD3
antibody (thick lines). Cells were treated with the indicated reagents for 16 h.
The dotted lines indicated the staining with anti-ELAM antibody used as a
negative control.
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treatment with PDTC did not result in nonspecific or toxic
inhibition of gene expression; rehybridization of the blotted
membrane with a c-jun probe revealed that PDTC triggered a
simultaneous and sustained induction of the c-jun transcripts,
as previously described (18). Furthermore, c-jun mRNA levels
were synergistically increased by treatment with PDTC plus
the combination of PMA and ionophore under conditions in
which IL-2 transcription was completely abolished (Fig. 3A).
Since the proximal region of the IL-2 promoter (containing 275
bp of the upstream regulatory region of the IL-2 gene) includes
binding sites for a number of transcription factors that mediate
the induction of IL-2 gene expression (15), we next studied
whether the inhibitory effects of DTCs on IL-2 transcriptional
expression were mediated through inhibition of the IL-2 pro-
moter. The transcriptional activity of Jurkat cells transfected
with a reporter plasmid containing the IL-2 promoter region in
response to PMA plus ionophore was abrogated by treatment
with PDTC (Fig. 3B), DDTC, or disulfiram (data not shown).
Effects of PDTC on different transcription factors that reg-
ulate IL-2 promoter activity. We further dissected the mech-
anisms responsible for the PDTC-mediated inhibition of IL-2
transcription by analyzing the effects of the DTC on the activity
and binding of the transcription factors AP-1, NF-kB, and
NFAT, which have been shown to be critical for the activity of
the IL-2 promoter (15, 26, 46). As described for other stimuli
(52, 53), the potent activation by PMA plus ionophore of the
NF-kB reporter construct was blocked by pretreatment with
PDTC (Fig. 4A, upper). In contrast, the activity of an AP-1-
dependent reporter plasmid, which is stimulated by PDTC in
Jurkat cells (18), was synergistically increased by the combina-
tion of PMA plus ionophore and PDTC (data not shown).
Although AP-1 cooperates with NFAT to activate transcrip-
tion through the NFAT distal site of the IL-2 promoter, inter-
estingly, the transcriptional activation of a reporter construct
directed by this NFAT motif was abrogated by PDTC (Fig. 4A,
lower). The data obtained in these transfection experiments
correlated with the effect of PDTC on the DNA binding of
such transcription factors analyzed by EMSAs. Thus, the spe-
cific binding to NF-kB and NFAT probes from the human IL-2
promoter, strongly induced by PMA plus ionophore, was in-
hibited by DTC, whereas AP-1 DNA-binding activity was stim-
ulated by PDTC with the same nuclear extracts (Fig. 4B).
These effects were not due to a direct interference of PDTC
with DNA-transcription factor interaction, since exogenous
addition of PDTC to the binding reaction mixtures in EMSAs,
even at concentrations of 100 mM, did not affect the formation
of the specific complexes (data not shown). The effect of PDTC
on NF-kB DNA-binding activity was also observed in PBLs
activated by PMA plus ionophore (data not shown). In addi-
tion, PDTC completely blocked the specific binding to the
FIG. 2. Inhibition of IL-2 production by DTCs. Jurkat cells were either
pretreated or not with the indicated micromolar concentrations of DTCs for 2 h
and then were stimulated with 20 ng of PMA per ml plus 1 mM Ca21 ionophore
A23187 (P1Io). IL-2 was measured in the supernatants by enzyme-linked im-
munosorbent assay 20 h after stimulation. The levels of IL-2 detected in super-
natant of cells single treated with the different DTCs were the same as those in
the control cells (#60 pg/ml). The results are represented as the mean 6
standard deviation of two independent measures. Cell viability, tested by trypan
blue exclusion just before collection of the supernatants, was higher than 90% for
the different treatments.
FIG. 3. Effects of PDTC on IL-2 transcription. (A) Northern blot analysis
with poly(A)1 RNAs from Jurkat cells treated with PDTC or PMA plus A23187
(P1Io) or pretreated with PDTC for 2 h and then stimulated with PMA plus
A23187 (P1Io/PDTC) for the times indicated. After agarose electrophoresis and
blotting, the membrane was sequentially hybridized with IL-2, c-Jun, and b-actin
probes as indicated. C, control. (B) The transcriptional activity of IL-2 promoter
(bp 2326 to 145) was tested by transfection of Jurkat cells with Lipofectin for
8 h. Thirty-six hours posttransfection, cells were treated with PDTC or PMA plus
ionophore (P1Io) or were preincubated with PDTC for 2 h and further stimu-
lated with PMA plus ionophore (PDTC/P1Io) for 8 h. The results are expressed
as relative light units (R.L.U.) measured for 30 s. Results are representative of
five independent experiments. PDTC (50 mM), PMA (20 ng/ml), and Ca21
ionophore (1 mM) were used at the same doses in single or combined treatments
in panels A and B.
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NFAT probe in nuclear extracts from both PBLs activated by
PMA plus ionophore and T cells stimulated by cross-linking
with immobilized T3b anti-CD3 MAb (Fig. 4C and data not
shown).
Mechanisms of inhibition of NFAT by PDTC. The possible
effects of DTC on the activity of the NFAT cytosolic compo-
nent that could account for the observed inhibition were ana-
lyzed. Other drugs which block the binding and transactivating
abilities of NFAT, such as CsA and FK 506, target the phos-
phatase activity of calcineurin, thus preventing the subsequent
dephosphorylation and translocation of cytosolic NFAT (28,
55). Therefore, we explored whether PDTC affected the de-
phosphorylation of NFAT1/p and its translocation to the nu-
cleus upon activation of Jurkat cells. Western blot analysis of
fractionated cellular extracts indicated that treatment with
PMA plus ionophore or ionophore alone induced the dephos-
phorylation and translocation to the nucleus of NFAT. As
previously reported (29, 49, 60, 65), the dephosphorylation or
translocation of NFAT was detected as early as 5 min, main-
tained for at least 90 min, and blocked by CsA (Fig. 5A).
Strikingly, exposure of cells to PDTC prior to the addition of
ionophore or PMA plus ionophore resulted in transient de-
phosphorylation and translocation of NFATp, and the bulk of
the transcription factor was found in the cytosolic extracts,
after 90 min of single or combined treatment with PDTC (Fig.
5A and data not shown). It is noteworthy that the mobility of
NFATp exported from the nucleus of PDTC-treated cells was
lower than that displayed by the phosphorylated form in un-
treated Jurkat cells (Fig. 5A). To further analyze the effects of
PDTC on the nuclear shuttling of NFATp, we performed im-
munocytochemical experiments in Jurkat cells transiently
transfected with HA-tagged full-length NFATp (33). As shown
in Fig. 5B, HA-tagged recombinant NFATp was found in the
cytoplasm of unstimulated cells and translocated to the nucleus
upon stimulation with PMA plus ionophore. In agreement with
the Western blot analysis, pretreatment with PDTC promoted
a rapid nuclear export of NFATp from the nucleus of cells
activated with PMA plus ionophore. In these cells, the tagged
recombinant NFATp protein was already detected in the cy-
toplasm of '50% of the transfected cells after 30 min of
activation, and the nuclear export was complete by 90 min (Fig.
5B, lower panel). Therefore, PDTC, by mechanisms at present
FIG. 4. PDTC-mediated changes in the activity and DNA binding of transcription factors that regulate IL-2 promoter activity. (A) Transcriptional activities of
NF-kB- and NFAT-dependent luciferase reporter plasmids were analyzed by transfection of Jurkat cells. Cells were transfected and treated with PDTC or PMA plus
ionophore or were pretreated with PDTC and then stimulated with PMA plus ionophore with the same doses and conditions described in the legend to Fig. 3. (B)
DNA-binding activities of NFAT, AP-1, and NF-kB factors were analyzed with the same pools of nuclear extracts from Jurkat cells either untreated or treated with
100 mM PDTC or 20 ng of PMA per ml plus 1 mM ionophore (P1Io) for 4 h. For the combined treatment (PDTC/P1Io), PDTC was incubated for 2 h, followed by
a 4-h stimulation with P1Io at the same doses as those used in separate treatments. Specific binding was tested by addition to the binding reaction mixtures of 30-fold
molar excess of unlabeled homologous oligonucleotide (Comp. 1). (C) NFAT DNA-binding activity was analyzed for nuclear extracts from purified T lymphocytes
stimulated with cross-linked T3b anti-CD3 antibody for 15, 60, and 120 min. Cells were pretreated with PDTC for 2 h and further stimulated with anti-CD3 antibody
(PDTC/anti-CD3) for the indicated times.
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unknown, accelerates the shuttling of the transcription factor
in activated Jurkat cells.
In view of the requirement of sustained activation to pro-
mote NFAT-dependent transcription (65), we next investi-
gated whether PDTC affected the transactivating ability of
NFAT in activated cells. For this purpose, we performed co-
transfection experiments with a chimeric expression plasmid
encoding the NH2-terminal transactivation domain of NFATp
fused to the GAL4 DBD (32), together with a GAL4-Luc
reporter plasmid. As shown in Fig. 6, PDTC prevented the
transactivation function of NFATp induced by PMA plus iono-
phore. As controls, in parallel transfections, we included
GAL4 expression vectors encoding the transactivation domain
of c-Jun (GAL4–c-Jun wild type). Strikingly, PDTC inhibited
the transactivation by the GAL4-NFAT hybrid induced by
PMA plus ionophore, under the same conditions that strongly
increased the transactivation by the GAL4-c-Jun construct. As
occurred with the activity of an AP-1 reporter construct, PDTC
and PMA-ionophore strongly synergized activating the GAL4–
c-Jun construct. As an additional control, we also included in
the experiments a plasmid identical to the GAL4–c-Jun wild
type but double mutated in serines located at positions 63 and
73 (GAL4–c-Jun S1 1 S2) (45). Transactivation by this mu-
tated plasmid was not affected at all by treatments with the
stimuli that strongly increased the activity of the wild type (Fig.
6).
In order to investigate whether the effect of PDTC on the
rapid nuclear export of NFATp in activated Jurkat cells was
also operative in other cell types, we carried out Western
blotting experiments with the gd T-cell line PEER as well as
with PBLs. The phosphorylated status of NFATp was moni-
tored after different times of activation with ionophore in frac-
tionated cellular extracts of control and PDTC-treated cells.
As shown in Fig. 7, pretreatment of PBLs and PEER cells with
PDTC resulted in a rapid export of NFATp with a kinetics
similar to that displayed by Jurkat cells. Similarly, treatment
with the Ca21 ionophore induced the sustained presence of the
dephosphorylated form in the nucleus for at least 90 min in
these cells.
Since DTCs are able to activate JNK (18) and NFAT kinases
have been proposed to be involved and implicated in the ac-
tivation of the nuclear export of NFAT-4 and NFATc, respec-
tively (5, 61), we next analyzed whether NFATp was a target
for JNK. Solid-phase kinase analysis of JNK immunoprecipi-
tated from PBLs treated with either PMA plus ionophore or
PDTC indicated that both stimuli activated JNK activity, in-
ducing the phosphorylation of both NFATp and c-Jun (Fig. 8).
This striking result shows that NFATp is a substrate of JNK,
which is activated after PBL treatment with PDTC or PMA
plus ionophore.
Recent studies have shown that the composition of NFAT
changes during the T-cell activation process. Thus, NFATp is
rapidly activated and translocated to the nucleus within min-
utes after T-cell activation. Several hours after activation, the
bulk of NFATp is found in the cytoplasm, and other NFAT
family members have been suggested to mediate NFAT-de-
pendent sustained transcription (29). In addition, in NFAT1/
p-deficient mice, IL-2 gene expression upon signaling through
the TCR does not appear to be significantly affected (22, 72),
which suggests that other NFAT family members might play a
more relevant role in IL-2 gene activation or compensate for
the absence of NFAT1/p. Since we had observed complete
inhibition of NFAT-dependent transcription by PDTC, we de-
cided to analyze by EMSA its effects on the kinetics of binding
of NFAT in Jurkat cells activated with PMA plus ionophore.
These experiments showed that nuclear factor binding to the
NFAT probe, observed after 1 h of activation and further
increased after 4 and 8 h, was inhibited by PDTC at all differ-
ent times analyzed (Fig. 9, left). Serological analysis with the
67.1 specific anti-NFATp antibody revealed the predominant
presence of NFATp in nuclear extracts of cells activated for
1 h, while 8 h after activation, excess of the specific antiserum
only blocked and supershifted part of the NFAT complex (Fig.
9, right). Since NFATc has been shown to be transcriptionally
induced during T-cell activation (43) and is detected in the
nucleus later after T-cell stimulation (29), we performed
Northern blot analysis to determine whether the expression of
NFATc during activation was affected by PDTC. These exper-
iments revealed that the NFATc mRNA steady-state levels,
undetected in untreated Jurkat cells, were upregulated after
1 h of treatment with PMA plus ionophore, peaked at 4 h, and
were maintained at high levels for at least 8 h of activation.
Exposure to PDTC prior to the activation of the cells drasti-
cally inhibited NFATc gene expression at the times analyzed
(Fig. 10A and data not shown).
To determine whether nuclear export of NFATc was af-
fected by PDTC, we performed immunofluorescence analysis
of Jurkat cells transfected with HA-tagged NFATc(1–418).
FIG. 5. Rapid shuttling of NFATp induced by PDTC. (A) Western blot
analysis of fractionated cell extracts from Jurkat cells (106 per line in nuclear
lysates and 5 3 105 for total lysates) treated for 5 or 90 min with 20 ng of PMA
per ml plus 1 mM ionophore or 1 mM ionophore alone either pretreated or not
with PDTC (100 mM) or CsA (100 ng/ml) for 2 and 1 h, respectively. The
antiserum 67.1 was used for NFAT1/p detection. The electrophoretic mobilities
of the upper and lower bands corresponding to the phosphorylated and dephos-
phorylated forms of NFAT1, respectively, are indicated by arrows. C, control. (B)
Immunocytochemical staining of Jurkat cells transfected with HA-tagged
NFATp either untreated (2) or incubated with PDTC (50 mM) for 2 h. After
incubation, cells were stimulated with PMA (20 ng/ml) plus ionomycin (3 mM)
(PMA1ionomycin) for 30 or 90 min, fixed, and analyzed by immunofluorescence
with anti-HA antibody. The upper panel shows the subcellular localization of
HA-tagged NFATp in resting and stimulated cells, and the lower panel corre-
sponds to stimulation with PMA plus ionomycin in PDTC-pretreated cells.
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These experiments revealed that the translocation of recombi-
nant NFATc to the nucleus was detected as early as 15 min in
30 to 50% of the activated cells either treated or not with
PDTC. However, after 90 min, the nuclear export was total in
the cells treated with the DTC, whereas the staining pattern
remained nuclear in 90% of the cells activated in the absence
of PDTC (Fig. 10B).
Taken together, our results indicate that the combined ef-
fects of PDTC inhibiting the transactivating functions of
NFATp and the transcriptional induction of NFATc might well
account for the inhibition of binding and NFAT reporter-
dependent transcription of activated T cells. In addition, given
the critical role of NFAT in the IL-2 gene regulation (15, 46),
this combined effect could itself account for the inhibition of
IL-2 transcription and expression.
DISCUSSION
The transmission of signals derived from the T-cell stimula-
tion involves at least three different pathways mediated by Ras,
protein kinase C, and Ca21-calcineurin (15, 24). These path-
ways couple the signals from the plasma membrane with the
activation of transcription factors which regulate the expres-
sion of a large number of genes during the T-cell activation
program. Among these genes, those that code for cytokines
play a crucial role in the regulation of the immune response.
Cytokines control processes such as proliferation and differ-
entiation, as well as multiple effector functions of immune
cells. The fact that the immunosuppressive drugs CsA and FK
506 abrogate the cytokine transcription emphasizes not only
the relevance of cytokines in regulating the immune responses,
but also the central role that the Ca21-calcineurin pathway
plays in T lymphocytes. In this study, we showed that different
DTCs interfere with the T-cell activation process and analyzed
the effect of the pyrrolidine derivative of DTC (PDTC) on the
transcription factors that regulate IL-2 gene expression. This
analysis revealed that PDTC strongly inhibited NFAT activa-
tion by mechanisms different from those used by the immuno-
suppressive drugs CsA and FK 506.
We have shown that DTCs block IL-2 production and inhibit
the surface upregulation of T-cell activation antigens such as
CD69 and CD25 in both Jurkat and peripheral blood T cells.
FIG. 6. Opposite effects of PDTC on the transactivation of NFATp and c-Jun. Jurkat T cells were cotransfected by lipofection with 4 mg of a GAL4-Luc reporter
plasmid per ml together with 2 mg of the expression vectors coding for the fusion proteins GAL4-hNFAT1(1–415); GAL4–c-Jun (wt, wild type); the mutated version,
GAL4–c-Jun S1 1 S2; or the parental empty vector RSV-GAL4-DBD per ml for 8 h. After 36 h, cells were pretreated or not with 25 or 50 mM PDTC and further
stimulated with 20 ng of PMA per ml plus 1 mM A23187 for 3 h. The results are expressed as relative light units (R.L.U.) measured for 30 s and are representative
of three independent experiments.
FIG. 7. Shuttling of NFATp in PBLs and in the PEER T-cell line. Western blot analysis of fractionated cell extracts from PEER cells (A) or PBLs (B) (5 3 105
cells per sample in total and 106 cells for nuclear lysates) treated for the indicated times with 1 mM ionophore (Io) either pretreated or not with 100 mM PDTC for
2 h. For NFAT1/p detection, the antiserum 67.1 was used. The arrows indicate the phosphorylated and dephosphorylated forms of NFATp. C, control.
VOL. 17, 1997 DITHIOCARBAMATES BLOCK NFAT ACTIVATION 6443
Although these effects clearly reflect inhibition of the T-cell
activation process, DTCs by themselves also trigger signals
leading to a moderate surface expression of CD69. In fact, the
expression of CD69 in Jurkat cells stimulated with PMA plus
ionophore or in T cells activated with anti-CD3 MAb was not
completely inhibited by DTCs and remained at the same level
as those induced by the single treatment with the DTCs. This
activating effect resembles that exerted by PDTC on ICAM-1
activation in endothelial cells (40) and appears to be mediated
by transcriptional induction of the CD69 gene promoter
through AP-1 (9a). Given the fact that PDTC is able to induce
a sustained and strong activation of JNK in Jurkat T cells (18)
as well as in human PBLs (Fig. 8), such stimulation may also be
related to the observed CD69 upregulation.
Despite its ability to activate AP-1 in several cell types,
including T cells (18, 57), DTCs have been proposed as poten-
tial inhibitors of cytokine production in T cells by virtue of
their capacity to block NF-kB activation (52). The metal-che-
lating and oxygen radical-scavenging antioxidative properties
of these compounds have been suggested to mediate the inhi-
bition of this transcription factor (52). Strikingly, as occurs with
DTCs, other antioxidants such as NAC and thioredoxin not
only are inhibitors of NF-kB, but also activate AP-1 (38, 51, 52,
63). Although we have observed that the antioxidants NAC
and BHA also interfere with the T-cell activation process, their
inhibitory effects on the expression of activation antigens and
IL-2 production are weaker than those displayed by DTCs
(data not shown). In addition, we have found that NAC fails to
interfere with the nuclear shuttling of NFATp upon activation
of Jurkat cells (data not shown). Thus, the effects of NAC on
T-cell activation might be more related to its capacity to inhibit
NF-kB. Although these experiments suggest that the effects of
DTCs on NFAT are not related to their reactive oxygen inter-
mediate scavenger properties, we cannot exclude the possibil-
ity that the stronger antioxidative potency of DTCs could ac-
count for such effects.
The relative contributions of different members of the
NFAT family of transcription factors to the transcriptional
activation of the IL-2 gene are not completely understood. It
seems that NFATp plays a major role in early T-cell activation
and then is slowly deactivated (29), whereas the bulk of
NFATc is induced and activates transcription later on. How-
ever, in NFAT1/p-deficient mice, IL-2 transcription upon sig-
naling through the TCR is not significantly affected (22, 72),
which suggests that other NFAT family members may play a
more important role in the transcriptional regulation of the
IL-2 gene. Thus, the inhibitory effects of PDTC on NFATc
may be more relevant to the inhibition of IL-2 than that ex-
erted on the transactivating abilities of NFATp. The promi-
nent role of NFATc in this process would also be consistent
with the severe inhibition that the expression of a transdomi-
nant negative of NFATc exerts on the transcriptional activa-
tion of the IL-2 promoter construct (reference 43 and data not
shown). Although we have not addressed the mechanisms by
which PDTC blocks NFATc gene expression, it is tempting to
speculate that the transcription factors inhibited by PDTC
would also be involved in the transcriptional regulation of
NFATc. In such case, although we do not rule out that DTCs
may affect other transcription factors, NF-kB or NFAT family
members would be good candidates for regulation of NFATc
gene transcription. Initially, the presence of normal levels of
NFATc in NFATp-deficient mice would argue against an es-
sential role of NFATp in the regulation of NFATc expression.
However, a putative role of NFATp in regulating NFATc-
inducible expression cannot be excluded, and compensatory
mechanisms may also operate through other family members,
such as NFATx, in the deficient mice. The functional charac-
terization of the cis-acting and trans-acting elements involved
in the transcriptional regulation of the NFATc gene promoter
will clarify which factors are actually involved in this regula-
tion.
In contrast to the sustained translocation to the nucleus
induced by ionophore or PMA plus ionophore (29), PDTC
triggered a rapid nuclear shuttling of NFATp in the different
T-cell types analyzed. Recently, calcium signaling has been
shown to induce an association between the NFAT4 family
member and calcineurin, which are both imported to the nu-
cleus as a complex. Once in the nucleus, a putative kinase has
been proposed to promote the nuclear export of the transcrip-
tion factor (61). Furthermore, glycogen synthase kinase-3 has
been shown to phosphorylate critical serines of NFATc that
are required for nuclear export and to enhance the nuclear exit
of the transcription factor. However, glycogen synthase ki-
nase-3 activity requires the previous phosphorylation of
NFATc by an unknown kinase(s) that could directly phosphor-
ylate NFATc (5). In this context, it is tempting to speculate
about the existence of an NFAT kinase activated by PDTC that
would be responsible for the accelerated induction of the nu-
clear export of NFAT. Supporting this hypothesis is the fact
that NFATp exported from the nucleus of PDTC-treated cells
FIG. 8. JNK phosphorylates NFATp in vitro. PBLs treated with 20 ng of
PMA per ml plus 1 mM ionophore (P1Io) or 100 mM PDTC were lysed and
immunoprecipitated with antibody specific to JNK1 at the indicated times. The
immune complexes were incubated with GST–c-Jun(1–79) or GST-NFATp(1–
415) in kinase buffer in the presence of [g-32P]ATP for 20 min. The reactions
were stopped and separated on SDS–12% polyacrylamide gels.
FIG. 9. Kinetics analysis and contribution of NFATp to DNA-binding activ-
ity of NFAT. DNA-binding activity of NFAT was analyzed in nuclear extracts
from Jurkat cells treated for 1, 4, and 8 h with PDTC or PMA plus ionophore
(P1Io) or preincubated for 2 h with PDTC and then treated with PMA plus
ionophore for different times as indicated (left panel). C, control. Nuclear ex-
tracts from Jurkat cells stimulated with the PMA plus ionophore for 1 and 8 h
were analyzed by EMSA in the presence or absence of 0.5 ml of the anti-NFATp
antibody 67.1. The autoradiograph was overexposed to visualize the supershifted
complex, indicated by an arrow (right panel). Doses of 100 mM PDTC, 20 ng of
PMA per ml, and 1 mM A23187 were used in single or combined treatments.
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displays a lower mobility than that of untreated cells that could
be due to hyperphosphorylation of the transcription factor.
Since we have shown that NFATp is directly phosphorylated by
JNK and that PDTC exerts a potent and sustained activation of
JNK in Jurkat cells (18), as well as in PBLs, it is conceivable
that the sustained activation of JNK may be related to the
rapid nuclear exit of NFATp. However, in vivo experiments
will be required to elucidate whether JNK is indeed involved in
regulating the shuttling of NFATp. Alternatively, a possible
late effect of PDTC involving inhibition of calcineurin that
would allow normal kinases to reverse NFATp dephosphory-
lation cannot be excluded. Independently of the mechanisms
by which PDTC promotes the accelerated export of NFATp
from the nucleus of activated cells, this rapid export may well
account for its inhibitory effect on the transactivation of
NFATp, and the identification of the cellular targets involved
in this process may help the design of new strategies and drugs
for immunosuppressive purposes. In this regard, it is important
to note that maintenance of NFAT in the nucleus as a result of
a sustained increase in Cai
21, but not a transient increase, has
been shown to be required to switch on IL-2 gene expression in
activated Jurkat T cells (65).
The inhibition of activation both NF-kB and NFAT by
DTCs suggests a potential use of these agents as immunosup-
pressive drugs. NFAT and NF-kB control the transcription of
many cytokine genes and are involved in the response to proin-
flammatory stimuli in a number of cell types and in the T-cell
activation process (3, 46). The effects of DTCs are not re-
stricted to transformed T-cell lines; in primary human T lym-
phocytes, PDTC has been shown to inhibit cell proliferation
and CD25 expression in response to costimulation with anti-
CD28 and anti-CD2 MAbs (1), as well as the IL-2 secretion
induced by costimulation with antibodies against TCR-CD3
and CD28 (30). As occurs with Jurkat T cells, in activated
PBLs, DTCs inhibit cell surface expression of activation anti-
gens and binding of NFAT and NF-kB to their cognate se-
quences in EMSAs. Based on their effects in vitro, it will be
very important to analyze the potential of DTCs as immuno-
suppressive drugs in vivo. In fact, DDTC has already been used
in human immunodeficiency virus-infected patients, and ben-
eficial effects of the drug in delaying AIDS symptoms have
been reported (47). However, several effects of DTCs observed
in vitro must be taken into consideration when the use of these
drugs in vivo is evaluated. First of all, DTCs activate AP-1 in a
number of cell types. This effect has been involved in the
upregulation of ICAM-1 expression in endothelial cells (40),
and it is likely to mediate CD69 membrane expression and the
activation of other AP-1-dependent genes. Although the over-
all effect of DTCs in cells analyzed seems to be inhibitory,
AP-1-dependent gene activation could potentially interfere
with the putative anti-inflammatory properties of these com-
pounds. In addition, overdosage or long-term treatments with
PDTC can desensitize cells to the inhibitory effect of the drug
(53). Furthermore, although DTCs have been found to prevent
apoptotic cell death (7, 13, 56), they have also been involved in
triggering of apoptosis (42, 71). Although at the times and
doses analyzed, DTCs do not affect the viability of Jurkat cells,
we have observed that longer treatments with these agents
result in loss of cell viability associated with a clear pattern of
apoptosis. Since a role for NF-kB activation in the suppression
of signals leading to cell death has been suggested (4, 6, 68, 69),
it is possible that some genes whose expression is regulated by
NF-kB may be involved in protective mechanisms against pro-
grammed cell death. Hence, these possible effects must be
contemplated in cases in which in vivo protocols involving
long-term treatments with DTCs are used. On the other hand,
a potential benefit of DTCs versus other immunosuppressive
drugs is related to DTC’s ability to target other cells apart from
those of the immune system. Thus, whereas CsA and FK 506
mediate in vivo immunosuppression preferentially through T
lymphocytes, PDTC can also efficiently block cytokine produc-
tion and the induction of the VCAM-1 and E-selectin expres-
sion in endothelial cells activated by proinflammatory stimuli
(36, 41). Since VCAM-1 and ELAM-1 are adhesion molecules
involved in leukocyte-endothelial cell interactions required for
the recruitment and emigration of cells of the immune system
FIG. 10. Effect of PDTC on gene expression and nuclear translocation of NFATc in activated cells. (A) Poly(A)1 mRNAs from Jurkat cells treated with 50 mM
PDTC (PDTC) or 20 ng of PMA per ml plus 1 mM A23187 (P1Io) or pretreated for 2 h with 50 mM PDTC and then stimulated with 20 ng of PMA per ml plus 1
mM ionophore (PDTC/P1Io) for 1 and 4 h were isolated, separated by agarose gel electrophoresis, transferred onto a nitrocellulose membrane, and sequentially
hybridized with NFATc and b-actin cDNA probes. C, control. (B) Staining of Jurkat cells transfected with HA-tagged NFATc pretreated or not with 50 mM PDTC
for 2 h and further stimulated with 20 ng of PMA per ml plus 1 mM ionophore for 15 or 90 min. After incubation, cells were fixed and analyzed by immunofluorescence
with anti-HA antibody. The subcellular localization of HA-tagged NFATc in resting and activated cells is shown in the upper panels, and that of PDTC-pretreated cells
is represented in the lower panels.
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to inflamed tissues, it will be very important to determine
whether such processes are affected by DTCs in vivo.
The ability of DTCs to inhibit the transcriptional activation
of both NFAT and NF-kB in a variety of immunocompetent
cells and the fact that these compounds have previously been
used as pharmaceutical drugs support their potential use as
immunosuppressants. While such use will require a careful and
thorough analysis by evaluation of the overall effects of DTCs
in vivo, DTCs have been shown to be useful probes for study-
ing signaling pathways and regulation of transcription factors
implicated in the T-cell activation process.
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